ALX Oncology (ALXO) News Today → Trump convicted... now what? (From Stansberry Research) (Ad) Free ALXO Stock Alerts $9.01 -0.27 (-2.91%) (As of 06/7/2024 08:51 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 10 at 8:12 AM | americanbankingnews.comALX Oncology (NASDAQ:ALXO) Earns Buy Rating from HC WainwrightJune 9 at 9:16 AM | marketbeat.comVestal Point Capital LP Buys New Shares in ALX Oncology Holdings Inc. (NASDAQ:ALXO)Vestal Point Capital LP bought a new stake in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 1,655,000 shares of the company's stock, valued at approximately $24,643,000. ALX OJune 7 at 8:26 AM | insidertrades.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Jaume Pons Sells 20,000 SharesJune 6, 2024 | marketbeat.comJaume Pons Sells 20,000 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) StockALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) insider Jaume Pons sold 20,000 shares of the firm's stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $8.43, for a total value of $168,600.00. Following the completion of the transaction, the insider now owns 604,205 shares in the company, valued at approximately $5,093,448.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.June 6, 2024 | americanbankingnews.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Recommendation of "Moderate Buy" from BrokeragesJune 3, 2024 | marketbeat.comALX Oncology (NASDAQ:ALXO) Trading Down 6.6%ALX Oncology (NASDAQ:ALXO) Shares Down 6.6%June 2, 2024 | globenewswire.comALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder CancerJune 2, 2024 | americanbankingnews.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Sees Significant Increase in Short InterestMay 31, 2024 | americanbankingnews.comALX Oncology (NASDAQ:ALXO) Stock Rating Reaffirmed by Cantor FitzgeraldMay 29, 2024 | marketbeat.comALX Oncology (NASDAQ:ALXO) Rating Reiterated by Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating on shares of ALX Oncology in a research note on Wednesday.May 29, 2024 | globenewswire.comALX Oncology Announces Participation in the Jefferies Global Healthcare ConferenceMay 24, 2024 | marketbeat.comALX Oncology (NASDAQ:ALXO) Shares Down 5.8% ALX Oncology (NASDAQ:ALXO) Trading Down 5.8%May 24, 2024 | markets.businessinsider.comBuy Rating for ALX Oncology Amid Impressive Evorpacept and Padcev Combination Trial ResultsMay 23, 2024 | marketbeat.comALX Oncology (NASDAQ:ALXO) Sees Strong Trading VolumeALX Oncology (NASDAQ:ALXO) Sees Unusually-High Trading VolumeMay 21, 2024 | marketbeat.comALX Oncology (NASDAQ:ALXO) Trading Up 2.6%ALX Oncology (NASDAQ:ALXO) Trading 2.6% HigherMay 16, 2024 | insidertrades.comInsider Selling: ALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Sells 12,000 Shares of StockMay 16, 2024 | marketbeat.comALX Oncology (NASDAQ:ALXO) Shares Down 3.8% Following Insider SellingALX Oncology (NASDAQ:ALXO) Trading Down 3.8% Following Insider SellingMay 16, 2024 | finance.yahoo.comInsider Sale: Chief Medical Officer of ALX Oncology Holdings Inc (ALXO) Sells SharesMay 15, 2024 | marketbeat.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Sells $191,280.00 in StockALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) insider Sophia Randolph sold 12,000 shares of ALX Oncology stock in a transaction on Monday, May 13th. The shares were sold at an average price of $15.94, for a total value of $191,280.00. Following the completion of the sale, the insider now directly owns 330,349 shares of the company's stock, valued at $5,265,763.06. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.May 14, 2024 | marketbeat.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Sees Significant Decline in Short InterestALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) was the recipient of a large decline in short interest in April. As of April 30th, there was short interest totalling 3,160,000 shares, a decline of 14.4% from the April 15th total of 3,690,000 shares. Based on an average daily volume of 521,400 shares, the days-to-cover ratio is currently 6.1 days. Approximately 11.5% of the shares of the company are short sold.May 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), ALX Oncology Holdings (ALXO) and Quoin Pharmaceuticals (QNRX)May 10, 2024 | finance.yahoo.comALX Oncology Holdings Inc (ALXO) Q1 2024 Earnings Analysis: A Detailed Look at Financials and ...May 10, 2024 | investorplace.comALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q1 2024May 9, 2024 | globenewswire.comALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 9, 2024 | insidertrades.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Sells $318,400.00 in StockMay 7, 2024 | marketbeat.comALX Oncology (NASDAQ:ALXO) Trading Up 6.8%ALX Oncology (NASDAQ:ALXO) Shares Up 6.8%May 7, 2024 | globenewswire.comALX Oncology Appoints Allison Dillon as Chief Business OfficerMay 3, 2024 | msn.comRelay Therapeutics GAAP EPS of -$0.62 beats by $0.10, revenue of $10.01M beats by $9.09MApril 30, 2024 | finance.yahoo.comALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal CancerApril 30, 2024 | marketbeat.com66,211 Shares in ALX Oncology Holdings Inc. (NASDAQ:ALXO) Bought by abrdn plcabrdn plc bought a new position in ALX Oncology Holdings Inc. (NASDAQ:ALXO - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 66,211 shares of the company's stock, valued at approximately $986,000. abrdn plc owned aboutApril 29, 2024 | marketbeat.comALX Oncology (NASDAQ:ALXO) Hits New 52-Week High at $17.45ALX Oncology (NASDAQ:ALXO) Sets New 52-Week High at $17.45April 28, 2024 | marketbeat.comFederated Hermes Inc. Sells 54,824 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO)Federated Hermes Inc. decreased its stake in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO - Free Report) by 21.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 196,536 shares of the company's stock after selling 54,824 shares duApril 24, 2024 | globenewswire.comALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual MeetingApril 23, 2024 | marketbeat.comALX Oncology (NASDAQ:ALXO) Trading Up 9.1%ALX Oncology (NASDAQ:ALXO) Trading 9.1% HigherApril 22, 2024 | marketbeat.comALX Oncology (NASDAQ:ALXO) Shares Down 4.8% ALX Oncology (NASDAQ:ALXO) Stock Price Down 4.8%April 20, 2024 | investing.comAlx Oncology's president & CSO sells $710k in stockApril 19, 2024 | insidertrades.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Sells $710,000.00 in StockApril 18, 2024 | marketbeat.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Jaume Pons Sells 50,000 SharesALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) insider Jaume Pons sold 50,000 shares of the stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $14.20, for a total value of $710,000.00. Following the completion of the sale, the insider now directly owns 604,205 shares of the company's stock, valued at $8,579,711. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.April 18, 2024 | seekingalpha.comALX Oncology: Trying To Justify The HypeApril 18, 2024 | seekingalpha.comENPH, OCUL and ITCI are among after hour moversApril 17, 2024 | marketbeat.comALX Oncology (NASDAQ:ALXO) Trading Up 6.5%ALX Oncology (NASDAQ:ALXO) Shares Up 6.5%April 16, 2024 | marketbeat.comALX Oncology (NASDAQ:ALXO) Sees Large Volume IncreaseALX Oncology (NASDAQ:ALXO) Sees Large Volume IncreaseApril 13, 2024 | uk.investing.comALX Oncology hold rating reiterated with steady stock target by StifelApril 12, 2024 | marketbeat.comALX Oncology's (ALXO) Overweight Rating Reiterated at Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating on shares of ALX Oncology in a research report on Friday.April 11, 2024 | marketbeat.comALX Oncology (NASDAQ:ALXO) Trading 4.2% Higher ALX Oncology (NASDAQ:ALXO) Stock Price Up 4.2%April 11, 2024 | markets.businessinsider.comBuy Rating on ALX Oncology Holdings Amid Strong Clinical Data and Favorable rNPV AnalysisApril 10, 2024 | marketbeat.comALX Oncology's (ALXO) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $20.00 price objective on shares of ALX Oncology in a research report on Wednesday.April 9, 2024 | globenewswire.comALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)April 8, 2024 | markets.businessinsider.comBuy Rating Justified by Promising Evorpacept Trial Results and Market PotentialApril 6, 2024 | finance.yahoo.comALX Oncology Holdings Inc (ALXO) Insider Sells Shares Get ALX Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ALXO and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump convicted... now what? (Ad)Unexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. But while the Left celebrates his conviction... and the Right rallies around him... the average American is not prepared for what happens next. Which is why it's so important to access this presentation while it's still available online. ALXO Media Mentions By Week ALXO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALXO News Sentiment▼0.930.76▲Average Medical News Sentiment ALXO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALXO Articles This Week▼62▲ALXO Articles Average Week Get ALX Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ALXO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Atea Pharmaceuticals News Today I-Mab News Today Evotec News Today Protagonist Therapeutics News Today NewAmsterdam Pharma News Today Harmony Biosciences News Today Edgewise Therapeutics News Today Taro Pharmaceutical Industries News Today Syndax Pharmaceuticals News Today Ardelyx News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALXO) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersAlert: Your Bank is Dying – Act Now or Lose Everything!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put...Priority Gold | SponsoredTrump convicted... now what?Unexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | Sponsored